New strategy aims to zap remaining tumors in lung cancer patients
NCT ID NCT07379476
Summary
This trial is testing if adding targeted radiation or surgery to the standard drug osimertinib helps people with advanced lung cancer live longer without their cancer getting worse. It's for patients whose cancer has a specific genetic change (EGFR mutation) and who have only a few small tumors left after initial drug treatment. Researchers will compare continuing the drug alone versus the drug plus these local treatments to see which approach works better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Clinical Oncology, Prince of Wales Hospital
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.